Research ExplorerPublicationsA Rejected Hypothesis

A Rejected Hypothesis

Standard

A Rejected Hypothesis : Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction. / Abeck, Finn; Hansen, Inga; Wiesenhütter, Isabell; Brookman-May, Sabine D; Sharaf, Kariem; Kött, Julian; Bertlich, Mattis; Schneider, Stefan W; von Büren, Johannes.

In: TELEMED E-HEALTH, Vol. 29, No. 7, 07.2023, p. 1051-1056.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Abeck, F, Hansen, I, Wiesenhütter, I, Brookman-May, SD, Sharaf, K, Kött, J, Bertlich, M, Schneider, SW & von Büren, J 2023, 'A Rejected Hypothesis: Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction', TELEMED E-HEALTH, vol. 29, no. 7, pp. 1051-1056. https://doi.org/10.1089/tmj.2022.0290

APA

Abeck, F., Hansen, I., Wiesenhütter, I., Brookman-May, S. D., Sharaf, K., Kött, J., Bertlich, M., Schneider, S. W., & von Büren, J. (2023). A Rejected Hypothesis: Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction. TELEMED E-HEALTH, 29(7), 1051-1056. https://doi.org/10.1089/tmj.2022.0290

Vancouver

Abeck F, Hansen I, Wiesenhütter I, Brookman-May SD, Sharaf K, Kött J et al. A Rejected Hypothesis: Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction. TELEMED E-HEALTH. 2023 Jul;29(7):1051-1056. https://doi.org/10.1089/tmj.2022.0290

Bibtex

@article{49a35ac3d2b84412aefe72e3218289a2,
title = "A Rejected Hypothesis: Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction",
abstract = "Background: Adherence to dermatological treatment is described as poor. Empathy and open communication in the physician-patient relationship has been proven to improve adherence. As direct-to-consumer teledermatology enables patients to access dermatological consultations without in-person interactions, we hypothesized treatment adherence in teledermatology to be low. Methods: The objective of the study was to examine treatment adherence in teledermatology. This retrospective cross-sectional study used data from patients treated through a German direct-to-consumer teledermatology platform between July 2021 and April 2022. Additional information was collected through voluntary follow-up questionnaires provided to patients to assess individual treatment success, treatment-related adverse events, and treatment adherence. Results: Data collection included 771 patients; 61.6% (475/771) were women (mean age 35 years). In 46% (355/771), skin disease had been present for <3 months before teleconsultation. Of all patients who answered the follow-up questionnaire (n = 228), 28.5% (65/228) reported treatment-related adverse events, with skin dryness being the most common (56.9%, 37/65). Adverse events resulting in treatment discontinuation were reported in 1.3% (3/228) of all cases. Improvement in skin condition on therapy was described by 75.4% (172/228). In 85.5% (195/228), full treatment adherence was reported. Conclusion: This is the first study worldwide to examine data on treatment adherence in direct-to-consumer-teledermatology. Despite the lack of doctor-patient interaction, the results of our study demonstrate that most patients show high treatment adherence. Possible drivers contributing to high compliance rates could be the high proportion of new-onset skin diseases, the high treatment success of the prescribed therapies, and the low rate of serious adverse events.",
author = "Finn Abeck and Inga Hansen and Isabell Wiesenh{\"u}tter and Brookman-May, {Sabine D} and Kariem Sharaf and Julian K{\"o}tt and Mattis Bertlich and Schneider, {Stefan W} and {von B{\"u}ren}, Johannes",
year = "2023",
month = jul,
doi = "10.1089/tmj.2022.0290",
language = "English",
volume = "29",
pages = "1051--1056",
journal = "TELEMED E-HEALTH",
issn = "1530-5627",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - A Rejected Hypothesis

T2 - Phenomenon of High Treatment Adherence in Direct-to-Consumer Teledermatology Despite Lack of Direct Physician-Patient Interaction

AU - Abeck, Finn

AU - Hansen, Inga

AU - Wiesenhütter, Isabell

AU - Brookman-May, Sabine D

AU - Sharaf, Kariem

AU - Kött, Julian

AU - Bertlich, Mattis

AU - Schneider, Stefan W

AU - von Büren, Johannes

PY - 2023/7

Y1 - 2023/7

N2 - Background: Adherence to dermatological treatment is described as poor. Empathy and open communication in the physician-patient relationship has been proven to improve adherence. As direct-to-consumer teledermatology enables patients to access dermatological consultations without in-person interactions, we hypothesized treatment adherence in teledermatology to be low. Methods: The objective of the study was to examine treatment adherence in teledermatology. This retrospective cross-sectional study used data from patients treated through a German direct-to-consumer teledermatology platform between July 2021 and April 2022. Additional information was collected through voluntary follow-up questionnaires provided to patients to assess individual treatment success, treatment-related adverse events, and treatment adherence. Results: Data collection included 771 patients; 61.6% (475/771) were women (mean age 35 years). In 46% (355/771), skin disease had been present for <3 months before teleconsultation. Of all patients who answered the follow-up questionnaire (n = 228), 28.5% (65/228) reported treatment-related adverse events, with skin dryness being the most common (56.9%, 37/65). Adverse events resulting in treatment discontinuation were reported in 1.3% (3/228) of all cases. Improvement in skin condition on therapy was described by 75.4% (172/228). In 85.5% (195/228), full treatment adherence was reported. Conclusion: This is the first study worldwide to examine data on treatment adherence in direct-to-consumer-teledermatology. Despite the lack of doctor-patient interaction, the results of our study demonstrate that most patients show high treatment adherence. Possible drivers contributing to high compliance rates could be the high proportion of new-onset skin diseases, the high treatment success of the prescribed therapies, and the low rate of serious adverse events.

AB - Background: Adherence to dermatological treatment is described as poor. Empathy and open communication in the physician-patient relationship has been proven to improve adherence. As direct-to-consumer teledermatology enables patients to access dermatological consultations without in-person interactions, we hypothesized treatment adherence in teledermatology to be low. Methods: The objective of the study was to examine treatment adherence in teledermatology. This retrospective cross-sectional study used data from patients treated through a German direct-to-consumer teledermatology platform between July 2021 and April 2022. Additional information was collected through voluntary follow-up questionnaires provided to patients to assess individual treatment success, treatment-related adverse events, and treatment adherence. Results: Data collection included 771 patients; 61.6% (475/771) were women (mean age 35 years). In 46% (355/771), skin disease had been present for <3 months before teleconsultation. Of all patients who answered the follow-up questionnaire (n = 228), 28.5% (65/228) reported treatment-related adverse events, with skin dryness being the most common (56.9%, 37/65). Adverse events resulting in treatment discontinuation were reported in 1.3% (3/228) of all cases. Improvement in skin condition on therapy was described by 75.4% (172/228). In 85.5% (195/228), full treatment adherence was reported. Conclusion: This is the first study worldwide to examine data on treatment adherence in direct-to-consumer-teledermatology. Despite the lack of doctor-patient interaction, the results of our study demonstrate that most patients show high treatment adherence. Possible drivers contributing to high compliance rates could be the high proportion of new-onset skin diseases, the high treatment success of the prescribed therapies, and the low rate of serious adverse events.

U2 - 10.1089/tmj.2022.0290

DO - 10.1089/tmj.2022.0290

M3 - SCORING: Journal article

C2 - 36480808

VL - 29

SP - 1051

EP - 1056

JO - TELEMED E-HEALTH

JF - TELEMED E-HEALTH

SN - 1530-5627

IS - 7

ER -